A Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma
- You will be "randomized" into one of two study groups. The first group will receive the drug dasatinib in combination with bevacizumab. The second will receive a placebo (an inactive agent) in combination with bevacizumab. Randomization means that you are put into a group by chance (as in the flip of a coin).
- Neither you nor your doctor can choose the group you will be in.